In an industry where most companies over-promise and under-deliver, a company that exceeds even the most optimistic expectations is a unique phenomenon.
Yesterday morning, while most eyes were still turned towards Chicago following ASCO, Micromet (NASDAQ:MITI) managed to present another impressive set of clinical data in the picturesque town of Lugano, Switzerland. The data is from an ongoing phase I trial for the evaluation of the company’s lead product, MT103, in Non-Hodgkin’s Lymphoma [NHL], a trial which had already produced impressive results.
Although the actual scientific poster is not yet publically available, according to the company’s recent press release, MT103 led to an impressive clinical response among 7 heavily pre-treated NHL patients.
When given MT103 at the highest dose so far in the trial, all 7 patients achieved a significant reduction in tumor burden in the form of either a complete or partial response. Importantly, those responses are durable and are currently ongoing in all seven patients, with the longest remission ongoing for more than one year.
Evidently, the data is still very preliminary, as it is being derived from a small non-controlled phase I trial. Nevertheless, having 100% clinical activity with such durability in such a late-stage patient population bodes extremely well for the prospects of MT-103. More importantly, this is yet another validation of Micromet’s revolutionary BiTE platform, which can be utilized to develop an unlimited number of drug candidates for various cancer types.